Lenvatinib, an oral multikinase inhibitor, was approved by the US Food and Drug Administration in February 2015. In a pivotal phase III study of 392 patients with progressive radioiodine-refractory thyroid cancer, the overall response rate of patients receiving lenvatinib was 64.8%, with complete response in four patients. The median progression-free survival was 18.3 months in the lenvatinib arm versus 3.6 months in patients receiving placebo. Median overall survival was not reached in either arm. Lenvatinib is a promising new treatment for patients with radioiodine (iodine-131)-refractory differentiated thyroid cancer.
Introduction
Thyroid cancer is the most commonly encountered endocrine malignancy. 1 Most tumors arise from follicular epithelial cells and are known as differentiated thyroid cancers. 2 First-line therapy includes surgery, radioiodine ablation, and thyroid stimulating hormone (TSH) suppression. 3 Although the five-year relative survival rates are high, recurrent disease occurs in about a third of patients. 1 The prognosis for metastatic differentiated thyroid cancer varies, with a median 10-year survival of 42%. 4 Surgery and radioactive iodine (131-I) are the treatments of choice for metastatic disease. 3 Although use of radioiodine may produce remission or stable disease in many patients, about a third are refractory, resulting in a poor prognosis with a 10-year overall survival (OS) of about 10%. 5 Treatment options for this subgroup of patients are limited. Chemotherapeutic agents including etoposide, bleomycin, cisplatin, paclitaxel, or doxorubicin may be used, but their efficacy is limited and confers no survival advantage. 6 This paper will review the role of lenvatinib, an oral multi-targeted tyrosine kinase inhibitor recently approved for the treatment of iodine-131-refractory differentiated thyroid cancer.
Pharmacology
Lenvatinib, formerly known as E7080, targets vascular endothelial growth factor (VEGF), fibroblast growth factor receptor (FGFR), and platelet derived growth factor receptor-alpha (PDGFR-a), as well as the RET and KIT proto-oncogene receptors. 7 Activation of tyrosine kinase receptors initiates the RAS and PI3K intracellular signaling pathways resulting in cell growth, differentiation, and survival. 8 Unchecked signaling of these pathways in malignancies may occur as a result of overexpression, mutation, translocation, or autocrine stimulation of the tyrosine kinase receptors and has been associated with tumor progression. 9 
Pharmacokinetics and metabolism
Lenvatinib is primarily metabolized by CYP3A4, with minor metabolism through oxidative and nonenzymatic routes. The majority of excretion (64%) is via the feces, with an additional 25% excreted in the urine. It is highly protein bound with a terminal halflife of 28 h. 10 The pharmacokinetic and drug interaction profile of lenvatinib was characterized in a series of studies by Shumaker et al. 11 The oral clearance of lenvatinib in healthy volunteers was 10.1 L/h, and the volume of distribution was 322 L.
A single 10 mg dose of lenvatinib was administered to 18 patients with hepatic impairment (5 mg for those with severe disease). 12 When compared to age, gender, and BMI matched healthy controls, the AUC and T 1/2 were significantly increased only in subjects with severe hepatic impairment.
Lenvatinib exposure in 18 subjects with renal dysfunction (creatinine clearance ranging from <30 to 89 mL/min) was evaluated following administration of a single 24 mg dose. 13 Patients with end stage renal disease (creatinine clearance <15 mL/min) were excluded. When compared to healthy volunteers, no changes in AUC were noted.
When ketoconazole 14 or rifampicin 15 were administered concurrently with lenvatinib, both AUC, C max and T 1/2 were affected, but these differences were not considered clinically significant.
A study of 52 healthy subjects found no prolongation of the QTc interval following administration of a single 25 mg dose of lenvatinib. 16 
Clinical efficacy
A summary of lenvatinib clinical trials is presented in Table 1 .
Phase I
Yamada et al. 17 conducted a phase I dose escalation study of lenvatinib in 27 patients with solid tumors. Angiogenic proteins and circulating endothelial and progenitor cells were evaluated as potential biomarkers. Lenvatinib was administered twice daily for 14 days every three weeks at doses ranging from 0.5 to 20 mg. The study patients received a median of four cycles of treatment, with a median treatment duration of 86 days. Partial response occurred in one patient and 21 patients had stable disease. Based on adverse effect profile and biomarker analysis, the investigators concluded that lenvatinib displayed anti-angiogenic activity and that the maximum tolerated dose (MTD) was 13 mg twice daily.
Nemunaitis et al. 18 compared continuous to intermittent lenvatinib dosing in a phase I study of 27 patients with advanced solid tumors. The patients received a median of three cycles of treatment. 19 Lenvatinib was administered continuously at doses ranging from 0.2 to 32 mg daily. Partial response occurred in seven patients (9%) and 38 patients had stable disease. The MTD was 25 mg daily. The investigators observed promising responses in patients with renal cancer and melanoma.
Nishio et al. 20 conducted a phase I dose escalation study in 28 patients with non-small cell lung cancer. Lenvatinib was administered twice daily continuously with carboplatin and paclitaxel given once every three weeks. The MTD was 4 mg twice daily. The objective response rate (ORR) was 68%, with partial response in 14 patients (64%), and complete response seen in one patient. The median duration of response (DOR) was 7.9 months, and the median progression-free survival (PFS) was 9.0 months. The investigators concluded that concurrent treatment with lenvatinib did not significantly alter the pharmacokinetics of paclitaxel or carboplatin, and that the three drug regimen showed promising activity in advanced non-small cell lung cancer.
A phase Ib dose escalation trial of 20 renal cell carcinoma patients was conducted by Molina et al. 21 Lenvatinib was administered at doses starting at 12 mg daily in combination with everolimus 5 mg daily. The maximum tolerated lenvatinib dose was 18 mg daily. The disease control rate (DCR) at the MTD was 81.8%, with partial response in more than one-third of patients. The median PFS was 330 days. Based on these preliminary results, the trial entered phase II to further study this combination treatment.
Phase II
Schlumberger et al. 22 conducted a phase II study in 59 patients with advanced medullary thyroid carcinoma. Almost half (44%) of the study patients had previously received anti-VEGFR therapy. Lenvatinib was administered continuously at a dose of 24 mg daily. At eight months of follow-up, the ORR was 36% (95% confidence interval [CI], 24-49%), with partial responses occurring in 21 patients. The median time to response (TTR) was 3.5 months, (95% CI, 1.9-3.7), and the median PFS was 9.0 months. Subgroup analysis revealed no difference in ORR based on previous anti-VEGFR treatment, but DOR, PFS, and OS favored anti-VEGFR naı¨ve patients. Based on these results, the authors concluded that further study of lenvatinib in advanced medullary thyroid cancer was indicated.
A phase II study by Sherman et al. 23 investigated 58 patients with radioiodine-refractory differentiated thyroid cancer. Lenvatinib was given at a dose of 24 mg daily. The response rate (RR) was 50%, with partial response observed in 29 patients. At eight months of follow-up, the median PFS was 12.6 months (95% CI, 10.4-14.1 months). On subgroup analysis, RRs were comparable regardless of prior anti-VEGFR therapy. The investigators concluded that lenvatinib was a potential new treatment of advanced differentiated thyroid cancer.
Takahashi et al. 24 conducted a phase II trial of lenvatinib in 35 patients with varying subtypes of advanced thyroid cancer, including nine with anaplastic histology. The investigator-assessed ORR was 25% in patients with medullary and 47.6% in patients with differentiated radioiodine-refractory disease. The authors reported an unprecedented ORR of 33% in patients with anaplastic thyroid cancer, with a median PFS of 5.5 months.
Phase III
A pivotal phase III randomized, double-blind, multicenter trial of 392 patients with progressive iodine-131-refractory thyroid cancer (SELECT) led to FDA approval of lenvatinib in February of 2015. 25 Schlumberger and colleagues randomized 392 patients in a 2:1 fashion to lenvatinib 24 mg daily or placebo. Patients receiving placebo could cross over to lenvatinib treatment at disease progression. The primary endpoint was PFS. The median PFS was18.3 months in the lenvatinib arm versus 3.6 months in the control group (hazard ratio (HR) 0.21, 99% CI 0.14-0.31, p < 0.001). The RR was 64.8% with lenvatinib, as opposed to 1.5% with placebo (p < 0.001). Complete response was observed in four patients. There was no significant difference in OS between the treatment arms [HR 0.73, 95% CI 0.5-1.07, p ¼ 0.10). A subgroup analysis determined that improvements in PFS were independent of age, gender, ethnicity, prior treatment, histology, BRAF, or RAS status. The majority of lenvatinib patients (76%) had grade 3 or higher adverse effects compared to 9.9% receiving placebo. There were six treatment-related fatalities.
Safety profile
The most commonly observed adverse effects in clinical trials of lenvatinib were hypertension, proteinuria, diarrhea, and nausea. [17] [18] [19] [20] [21] [22] [23] [24] [25] The investigators attributed the high incidence of serious adverse effects in the SELECT trial to the relatively long duration of treatment in study patients as compared to placebo (269.5 vs. 65.4 person-years). 26 Although lenvatinib was associated with considerable toxicity, most adverse effects were managed with pharmacologic intervention, dose interruption, and/or dose modification. [17] [18] [19] [20] [21] [22] [23] [24] [25] 
Dosage and administration
Lenvatinib is available as 4 mg and 10 mg capsules. 10 The recommended dosage in patients with normal renal and hepatic function is 24 mg at the same time each day without regard to meals. In severe hepatic or renal impairment, treatment should be initiated at 14 mg daily. Patients with dysphagia may dissolve capsules in water or apple juice. All patients should receive prophylaxis for moderately to highly emetogenic therapy. Renal, hepatic, and thyroid function, electrolytes, and proteinuria should be assessed at baseline and regularly throughout treatment. Lenvatinib should be held for grade 4 laboratory abnormalities, persistent or intolerable grade 2 or 3 adverse events or reversible posterior leukoencephalopathy syndrome. Once toxicity is resolved to grade 1 or less, treatment may be resumed at a dose of 20 mg daily, with reductions for subsequent occurrences to 14 mg, then 10 mg daily. If adverse reactions recur after dose reduction(s), consider treatment discontinuation. In the event of life-threatening hypertension or fistula, arterial thromboembolic complications, hepatic failure, nephrotic syndrome, gastrointestinal perforation, or grade 4 cardiac dysfunction or hemorrhage, treatment should be discontinued.
Summary
The incidence of thyroid cancer is increasing worldwide. 1 More than 64,000 new cases of thyroid cancer are expected in the United States alone in 2016. 27 Treatment options are limited and prognosis is poor for patients with radioiodine-refractory differentiated thyroid carcinoma. 5, 6 Lenvatinib was FDA approved in February 2015 as the second agent for the treatment of radioiodinerefractory differentiated thyroid cancer. 10 Although head-to-head trials of the first approved agent, sorafenib, and lenvatinib have not been conducted, a recent publication suggests that lenvatinib may be superior on the basis of PFS. 28 In May 2016, lenvatinib received additional FDA approval in combination with everolimus for secondline treatment of renal cell carcinoma following treatment with an anti-angiogenic agent. 10 Ongoing clinical trials are investigating its use as monotherapy or in combination with other agents in a wide range of tumor types.
29
Other FDA-approved multikinase inhibitors may provide additional treatment options for treatment of radioiodine-refractory differentiated thyroid cancer. Additional studies are needed to optimize and sequence therapies, effectively manage toxicities, overcome resistance, and improve durability of response.
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